US Healthcare ko lag sakta hai bada jhatka, India se dawaiyon par tariff ka khatra!
Agale mahine se India se aane wali dawaiyon par lagne wale tariff se US healthcare system ki halat kharab ho sakti hai. Reports ke mutaabik, Indian Commerce Minister Piyush Goyal ne US ka ek sudden trip kiya tha, jisme unhone trade deal ki baat ki aur tariffs ke impact ko kam karne ki koshish ki.
India se aati hain US ki aadhi generic dawaiyan!
US apni generic medicines ke liye India par kaafi dependent hai. Reports ke hisaab se, US mein use hone wali almost aadhi generic dawaiyan India se hi aati hain. Isse US healthcare system ko bohot bada fayda hota hai, aur IQVIA consulting firm ke ek study ke anusaar, 2022 mein hi Indian generics ne US ko $219 billion bachane mein madad ki.
Generic dawaiyon ka kamaal!
Generic dawaiyan, jo ki branded dawaiyon ke sasta version hote hain, US mein 10 mein se 9 prescriptions mein use hoti hain. Isliye, India ki pharma industry US healthcare system ke liye bohot important hai.
Tariffs se ho sakti hai dikkat!
Lekin, yeh naye tariffs is balance ko bigad sakte hain. Experts ka kehna hai ki tariffs ki wajah se kuch Indian generic dawaiyan market se gayab ho sakti hain, jisse dawaiyon ki kami ho sakti hai aur healthcare problems aur badh sakte hain. Yale University ki drug costing expert, Dr. Melissa Barber ne kaha ki tariffs se “demand-supply imbalances” aur bigad sakte hain, jiska asar uninsured aur gareeb logon par zyada padega, yeh baat BBC ki ek report mein kahi gayi hai.
Indian pharma companies bhi hain pareshan!
Indian pharma industry in tariffs se kaafi chintit hai. Sun Pharma aur Cipla jaisi companies ne apne business par tariffs ke negative impact ke bare mein baat ki hai. Sun Pharma ke chairman, Dilip Shanghvi ka kehna hai ki tariffs ki wajah se “manufacturing ko US shift karna justified nahi hai”, kyunki India aur US mein manufacturing cost mein bohot farak hai.
China se bhi mili hai warning!
US ne China se import par tariffs ka asar pehle hi dekh liya hai. Trump ke time se lekar ab tak, dawaiyon ke raw materials ki cost mein 20% ka izafa ho chuka hai. India ke liye, pharma sector sabse bada industrial export hai, aur US Indian generics ke liye ek important market hai. Agar US reciprocal tariffs lagata hai, toh generic aur specialty dono tarah ki dawaiyon ki keemat badh jayegi, jiska asar millions of Americans ki life par padega.
Kya hai solution?
In problems se bachne ke liye, kuch experts ka kehna hai ki India ko pharma goods par apne tariffs hata dene chahiye, jiska Indian economy par zyada asar nahi padega. Market expert Ajay Bagga ne BBC ko bataya ki “US se India mein drug export aadha billion dollar se bhi kam ka hai, toh iska impact negligible hoga”. Indian Pharmaceutical Alliance (IPA) ne bhi US drug exports par zero duty lagaane ki salah di hai, taki reciprocal levies se bacha ja sake. Lekin, yeh itna aasan nahi hai, kyunki iske liye India ki trade policies mein bade changes karne honge.
Sabki nazar trade deal par!
Aise mein, sabki nazar US aur India ke beech hone wale trade deal par hai. Former assistant US trade representative, Mark Linscott ka kehna hai ki “short term mein, new tariffs se kuch problems ho sakti hain, lekin mujhe lagta hai ki is saal ke end tak woh pehle trade agreement ke liye kaafi progress kar lenge”. Is negotiation ka result US healthcare system, Indian pharma industry, aur duniya bhar ke millions of logon ke liye bohot important hoga.
